Cargando…

Subcutaneous tocilizumab treatment in patients with severe COVID-19–related cytokine release syndrome: An observational cohort study

BACKGROUND: Patients with severe coronavirus disease 2019 (COVID-19) have elevated levels of acute phase reactants and inflammatory cytokines, including interleukin-6, indicative of cytokine release syndrome (CRS). The interleukin-6 receptor inhibitor tocilizumab is used for the treatment of chimeri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mastroianni, Antonio, Greco, Sonia, Apuzzo, Giovanni, De Santis, Salvatore, Oriolo, Carmela, Zanolini, Alfredo, Chidichimo, Luciana, Vangeli, Valeria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Research paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329292/ https://www.ncbi.nlm.nih.gov/pubmed/32766535 http://dx.doi.org/10.1016/j.eclinm.2020.100410

Ejemplares similares

Use of canakinumab and remdesivir in moderate-severe COVID-19 patients: A retrospective analysis
por: Mastroianni, Antonio, et al.
Publicado: (2023)

Early use of canakinumab to prevent mechanical ventilation in select COVID-19 patients: A retrospective, observational analysis
por: Mastroianni, Antonio, et al.
Publicado: (2021)

Convalescent plasma transfusion for pregnant patients with COVID-19
por: Mastroianni, Antonio, et al.
Publicado: (2021)

Indirect hyperbilirubinemia and jaundice during chronic hepatitis C in an HIV-infected patient treated with glecaprevir/pibrentasvir (GLE/PIB) and antiretroviral therapy (ART). The first reported case in Italy
por: MASTROIANNI, ANTONIO, et al.
Publicado: (2022)

Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports
por: Gaspari, Valeria, et al.
Publicado: (2020)

Does Tigecycline Have a Place in Therapy for Rickettsial Infection of the Central Nervous System?
por: Mastroianni, Antonio, et al.
Publicado: (2022)

Turicella otitidis central venous-related bacteremia during pediatric acute lymphoblastic leukemia
por: Mastroianni, Antonio, et al.
Publicado: (2023)

Occult Cytomegalovirus Cholangitis and Pancreatic Adenocarcinoma: A Case Report
por: Mastroianni, Antonio, et al.
Publicado: (2023)

Intrathecal tigecycline is a safe and effective treatment for central nervous system infections
por: Mastroianni, Antonio, et al.
Publicado: (2023)

The effect of tocilizumab on cytokine release syndrome in COVID-19 patients
por: de Cáceres, Carmen, et al.
Publicado: (2020)

Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19
por: Hassoun, Ali, et al.
Publicado: (2020)

Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome
por: Uslu, Sadettin
Publicado: (2020)

Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome
por: van Kraaij, Tom DA, et al.
Publicado: (2020)

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
por: Lauper, Kim, et al.
Publicado: (2018)

Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers
por: Nasa, Prashant, et al.
Publicado: (2020)

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab
por: Negoescu, Andra F., et al.
Publicado: (2014)

Subcutaneous Tocilizumab May Be Effective in Refractory Fibromyalgia Patients
por: Tang, Kuo-Tung, et al.
Publicado: (2023)

Correction: Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
Publicado: (2019)

Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date
por: Si, Stephanie, et al.
Publicado: (2020)

Tocilizumab in a child with acute lymphoblastic leukaemia and COVID-19-related cytokine release syndrome()
por: Velasco Puyó, Pablo, et al.
Publicado: (2020)

Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report
por: Radbel, Jared, et al.
Publicado: (2020)

Therapeutic Effect of Tocilizumab on Inhibiting Cytokine Release Syndrome in Severe Coronavirus Disease 2019 Patients
por: Xu, Lengnan, et al.
Publicado: (2022)

First, Do No Harm: Caution Against Use of Tocilizumab in COVID-19
por: Mastroianni, Fiore
Publicado: (2020)

Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
por: Liu, Danfei, et al.
Publicado: (2020)

Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes
por: Price, Christina C., et al.
Publicado: (2020)

Tocilizumab and Cytokine Release Syndrome in COVID-19 Pneumonia: Experience From a Single Center in Pakistan
por: Hassan, Muhammad, et al.
Publicado: (2021)

Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)
por: Burmester, Gerd R, et al.
Publicado: (2016)

Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2019)

Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies
por: Kaminski, Monica A., et al.
Publicado: (2020)

Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
por: Mekinian, Arsène, et al.
Publicado: (2023)

Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
por: Sarhan, Neven Mohamed, et al.
Publicado: (2023)

Case Study: A Patient with Asthma, Covid-19 Pneumonia and Cytokine Release Syndrome Treated with Corticosteroids and Tocilizumab
por: Schleicher, Gunter K, et al.
Publicado: (2020)

Can tocilizumab calm the cytokine storm of COVID-19?
por: Schulert, Grant S
Publicado: (2020)

Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2021)

Correction: Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
Publicado: (2023)

Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report
por: Burlo, Francesca, et al.
Publicado: (2023)

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
por: Zhang, Chi, et al.
Publicado: (2020)

Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome
por: Ali, Sabahat, et al.
Publicado: (2021)

P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vu44gd2q85e4eeh8v02toub7c0